Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

Samsung Bioepis' Q1 2025 report shows oncology, ophthalmology, and pegfilgrastim biosimilars have gained significant market share, while immunology, filgrastim, epoetin alfa, and insulin glargine ...

Around 59 companies are set to announce their third quarter results on Thursday, including key players like Ultratech Cement, ...